Compass Therapeutics appoints David Wurzer to Board and as Audit Committee Chairman

Compass Therapeutics, Inc.

David Wurzer appointed as Class III director effective Feb 8, 2023.
Wurzer named Chairman of Audit Committee; independent and audit committee financial expert.
Compensation: $45,000 cash retainer plus $10,000 for Audit Chair; 50,000-share option award vesting over 4 years.
Wurzer is CFO of Enko Chem, Inc.; no family relationships or reportable transactions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David Wurzer

Director

CMPX · Compass Therapeutics, Inc.

Effective: 2023-02-08
Filed: February 10, 2023, 6:59 PM ET

On February 8, 2023, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) approved the appointment of a new director to its Board: David Wurzer, CPA, CFO of Enko Chem, Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Wurzer was appointed as Director at Compass Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On February 8, 2023, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) approved the appointment of a new director to its Board: David Wurzer, CPA, CFO of Enko Chem, Inc.

View on SEC.gov

Compass Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-000899

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.